{
    "clinical_study": {
        "@rank": "141424", 
        "arm_group": {
            "arm_group_label": "Serelaxin", 
            "arm_group_type": "Experimental", 
            "description": "Serelaxin will be administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours."
        }, 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of an\n      intravenous infusion of serelaxin on top of standard of care therapy, in pediatric patients\n      with acute heart failure (AHF)"
        }, 
        "brief_title": "Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Heart Failure", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "INCLUSION CRITERIA:\n\n          -  Body weight \u22652.5 kg to \u2264120 kg\n\n          -  Hospitalized in an intensive care unit or step-down unit with the following:\n\n          -  - Signs and symptoms of acute heart failure of any etiology\n\n          -  - Stable dose of vasoactive and/or inotropic drugs\n\n          -  - For non-surgical patients echocardiographic evidence of reduced ventricular\n             function (ejection fraction <50% or fractional shortening <28%)\n\n          -  Systolic blood pressure (SBP) \u226525th percentile SBP for age and gender.\n\n        EXCLUSION CRITERIA:\n\n          -  Moderate to severe left ventricular outflow tract, mitral stenosis, or aortic arch\n             obstruction\n\n          -  Single ventricle physiology\n\n          -  Fixed pulmonary hypertension\n\n          -  Blood lactate levels >5 mmol/L at screening\n\n          -  Birth < 36 weeks post-conceptual age (for patients <1year old)\n\n          -  Confirmed or clinically suspected systemic infection or severe localized infection\n\n          -  Dyspnea or acute lung injury primarily due to non-cardiac causes\n\n          -  Patients with severe renal impairment, those known to have significant renal disease\n             and those having renal replacement therapy\n\n          -  High use of inotropic and/or vasoactive agents at screening\n\n          -  Electrocardiographic abnormalities\n\n          -  Solid organ transplant recipient within 1 year of transplantation or one who presents\n             with severe organ rejection\n\n        Other protocol defined inclusion/exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02151383", 
            "org_study_id": "CRLX030A2208", 
            "secondary_id": "2013-002847-28"
        }, 
        "intervention": {
            "arm_group_label": "Serelaxin", 
            "description": "Serelaxin will be administered intravenously for up to 48 hours.", 
            "intervention_name": "Serelaxin", 
            "intervention_type": "Drug", 
            "other_name": "RLX030"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Acute heart failure", 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Palo Alto", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94304"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bronx", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10467"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45229-3039"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29425"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Falls Church", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22042"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "13353"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Freiburg", 
                        "country": "Germany", 
                        "zip": "79106"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Muenchen", 
                        "country": "Germany", 
                        "zip": "80636"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gen\u00e8ve", 
                        "country": "Switzerland", 
                        "zip": "1211"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Germany", 
                "Switzerland"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Multicenter, Open-label, Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of RLX030 in Addition to Standard of Care in Pediatric Patients From Birth to <18 Years of Age, Hospitalized With Acute Heart Failure", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Germany: German Federal Institute for Drugs and Medical Devices (BfArM)", 
                "Switzerland: Swiss Agency for Therapeutic products (Swissmedic)", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Number of patients with adverse events (including confirmed systolic blood pressure decreases and worsening heart failure), serious adverse events and death will be analyzed in order to evaluate the safety and tolerability of intravenous serelaxin in AHF patients. Adverse events will be assessed by signs/symptoms, clinical laboratory and electrocardiographs.", 
                "measure": "Number of patients reported with adverse events, serious adverse events and death", 
                "safety_issue": "Yes", 
                "time_frame": "through 28 days"
            }, 
            {
                "measure": "Pharmacokinetic parameter: Css (steady state concentration)", 
                "safety_issue": "No", 
                "time_frame": "at 0, 2, 16, 22, 32, 40, 48 hr. during the infusion, at 0.5, 4, 8 hours post infusion or study drug discontinuation, and on day 28"
            }, 
            {
                "measure": "Pharmacokinetic parameter: CL (clearance)", 
                "safety_issue": "No", 
                "time_frame": "at 0, 2, 16, 22, 32, 40, 48 hr. during the infusion, at 0.5, 4, 8 hours post infusion or study drug discontinuation, and on day 28"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02151383"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline of arterial BP", 
                "safety_issue": "No", 
                "time_frame": "baseline, prior to each dose escalation, and at 24 hr. post end of infusion"
            }, 
            {
                "measure": "Change from baseline of central venous pressure (CVP)", 
                "safety_issue": "No", 
                "time_frame": "baseline, prior to each dose escalation, and at 24 hr. post end of infusion"
            }, 
            {
                "measure": "Change from baseline of left atrial pressure (LAP)", 
                "safety_issue": "No", 
                "time_frame": "baseline, prior to each dose escalation, and at 24 hr. post end of infusion"
            }, 
            {
                "measure": "Change from baseline of pulmonary artery pressure (PAP- systolic and diastolic)", 
                "safety_issue": "No", 
                "time_frame": "baseline, prior to each dose escalation, and at 24 hr. post end of infusion"
            }, 
            {
                "measure": "Change from baseline of central venous and arterial oxygen saturation", 
                "safety_issue": "No", 
                "time_frame": "baseline, prior to each dose escalation, and at 24 hr. post end of infusion"
            }, 
            {
                "measure": "Change from baseline of urine output", 
                "safety_issue": "No", 
                "time_frame": "baseline, prior to each dose escalation, and at 24 hr. post end of infusion"
            }, 
            {
                "measure": "Change from baseline of blood lactate levels", 
                "safety_issue": "No", 
                "time_frame": "baseline, prior to each dose escalation, and at 24 hr. post end of infusion"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}